Molecular Variations in Homologous Series. Vinylogues and Benzologues

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 275-289

  Wermuth, Camille G ^a  

^a Prestwick Chemical Inc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882552602     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00014-7     Document Type: Chapter

References (59)

1. Gerhardt, C. Principes de la classification sériaire. In Traite de Chimie Organique, Vol.1. Firmin Didot Frères: Paris, 1853, pp. 121-142.
2. Kim C.U., Lew W., Williams M.A., Wu H., Zhang L., Chen X., Escarpe P.A., Mendel D.B., Laver W.G., Stevens R.C. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem. 1998, 41:2451-2460.
3. 1 pharmacophore. J. Med. Chem. 1992, 35:4011-4019.
4. Cook L., Ternai B., Ghosh P. Inhibition of human sputum elastase by substituted 2-pyrones. J. Med. Chem. 1987, 30:1017-1023.
5. Thorsett E.D. Conformationally restricted inhibitors of angiotensin converting enzyme. Actualités de Chimie Thérapeutique 1986, Vol. 13:257-268. Société de Chimie Thérapeutique, Chatenay-Malabry. C. Combet-Farnoux (Ed.).
6. Eden J.M., Higginbottom M., Hill D.R., Horwell D.C., Hunter J.C., Martin K., Pritchard M.C., Rahman S.S., Richardson R.S., Roiberts E. Rationally designed "dipeptoid" analogues of cholecystokinin (CCK): N-terminal structure-affinity relationships of α-methyltryptophan derivatives. Eur. J. Med. Chem. 1993, 28:37-45.
7. Cheronis J.C., Whalley E.T., Nguyen K.T., Eubanks S.R., Allen L.G., Duggan M.J., Loy S.D., Bonham K.A., Blodgett J.K. A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J. Med. Chem. 1992, 35:1563-1572.
8. Wang W., Lown J.W. Anti-HIV-I activity of linked lexitropsins. J. Med. Chem. 1992, 35:2890-2897.
9. Press J.B., Wright W.B., Chan P.S., Haug M.F., Marsico J.W., Tomcufcik A.S. Thromboxane synthetase inhibitors and antihypertensive agents. 3. N-[(1H-Imidazol-1-yl)alkyl]heteroaryl amides as potent enzyme inhibitors. J. Med. Chem. 1987, 30:1036-1040.
10. 2 receptor antagonists. J. Med. Chem. 1992, 36:1175-1187.
11. Ginos J.Z., Stevens J.M., Nichols D.E. Structure-activity relationships of N-substituted dopamine and 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphtalene analogues: behavioral effects in lesioned and reserpinized mice. J. Med. Chem. 1979, 22:1323-1329.
12. Godfroid J.-J., Broquet C., Jouquey S., Lebbar M., Heymans F., Redeuilh C., Steiner E., Michel E., Coeffier E., Fichelle J., Worcel M. Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity. J. Med. Chem. 1987, 30:792-797.
13. Bustard T.M. Optimization of alkyl modifications by fibonacci search. J. Med. Chem. 1974, 17:777-778.
14. Santora N.J., Auyang K. Non-computer approach to structure-activity study. An expanded Fibonacci search applied to structurally diverse types of compounds. J. Med. Chem. 1975, 18:959-963.
15. Martin Y.C. Quantitative Drug Design, a Critical Introduction 1987, Marcel Dekker, Inc., New York, pp. 257-261.
16. Koelzer P.P., Wehr K.H. Beziehungen zwischen chemischer Konstitution un pharmakologischer Wirkung bei mehreren Klassen neure Lokalanaesthetica. Arzneimitt.-Forsch 1958, 8:544-550.
17. Funcke A.B.H., Ernsting M.J.E., Rekker R.F., Nauta W.T. Untersuchungen über Spasmolytica. 1. Mandelsäureester. Arzneimitt.-Forsch. 1953, 3:503-506.
18. A antagonists. J. Med. Chem. 1987, 30:239-249.
19. Magidson O.J., Strukow I.T. Die Derivate des 8-Aminochinolins als Antimalariapräparate. Mitteilung II: Der Einfluß der Länge der Kette in Stellung 8. Arch. Pharm. 1933, 271:569-580.
20. Herron D.K., Goodson T., Bollinger N.G., Swanson-Bean D., Wright I.G., Staten G.S., Thompson A.S., Froelich L.L., Jackson W.T. Leukotriene B4 receptor antagonists: the LY 255 283 series of hydroxyacetophenones. J. Med. Chem. 1992, 35:1818-1828.
21. Raison C.G., Standen O.D. The schistosomicidal activity of symmetrical diaminodiphenoxyalkanes. Br. J. Pharmacol. 1955, 10:191-199.
22. Fairley T.A., Tidwell R.R., Donkor I., Naiman N.A., Ohemeng K.A., Lombardy R.J., Bentley J.A., Cory M. Structure, DNA minor groove binding, and base pair specificity of alkyl- and aryl-linked bis(amidinobenzimidazoles) and bis(amidinoindoles). J. Med. Chem. 1993, 36:1746-1753.
23. Sugimoto H., Iimura Y., Yamanishi Y., Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 1996, 38:4821-4829.
24. Pattison F.L.M. Toxic Aliphatic Fluorine Compounds 1959, Elsevier, Amsterdam.
25. Ariëns E.J. Molecular Pharmacology 1964, Vol. 1. Academic Press, New York.
26. Beyer K.H., Baer J.E. Physiological basis for the action of newer diuretic agents. Pharmacol. Rev. 1961, Vol. 13:517-562.
27. Claisen L. Zu den O-Alkylderivaten des Benzoyl-acetons und den aus ihnen entstehenden Isooxazolen. Ber. dtsch. chem. Ges. 1926, 59:144-153.
28. Krishnamurthy S. The principle of vinylogy. J. Chem. Educ. 1982, 59:543-547.
29. Yamamoto H., Kaneko S.-I. Synthesis of 1-phenyl-2-styryl-3,5-dioxopyrazolidines as antiinflammatory agents. J. Med. Chem. 1970, 13:292-295.
30. Tenconi F., Barzaghi F. Attivita nicotinica di vinil-analoghi di esteri della colina. Boll. Chim. Pharmaceut. 1964, 103:569-575.
31. Zürcher G., Keller H.H., Kettler R., Borgulya J., Bonetti E.P., Eigenmann R., Da Prada M. Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv. Neurol. 1990, 53:497-503.
32. Nissinen E., Linden I.B. Biochemical and pharmacological properties of a peripherally acing catechol-O-methyltransferase inhibitor: entacapone. Naunyn Schmiedebergs Arch. Pharmacol. 1992, 346:262-266.
33. Wright S.W., Harris R.R., Kerr J.S., Green A.M., Pinto D.J., Bruin E.M., Collins R.J., Dorow R.L., Mantegna L.R., Sherk S.R., Covington M.B., Nurnberg S.A., Welch P.K., Nelson M.J., Magolda R.L. Synthesis, chemical, and biological properties of vinylogous hydroxamic acids: dual inhibitors of 5-lipoxygenase and IL-1 biosynthesis. J. Med. Chem. 1962, 35:4061-4068.
34. Reich S.H., Johnson T., Wallace M.B., Kephart S.E., Fuhrman S.A., Worland S.T., Mattews D.A., Hendrickson T.F., Chan F., Meador J., Ferre R.A., Brown E.L., DeLisle D.M., Patick A.K., Binford S.L., Ford C.E. Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation. J. Med. Chem. 2000, 43:1670-1683.
35. Babin P., Bourgeois P., Dunoguès J. Synthèse de l'éthynologue de l'acide acétylsalicylique. C. R. Acad. Sci. (Paris) 1976, 283:149-152.
36. Babin P., Cassagne A., Dunoguès J., Duboudin F., Lapouyade P. Ethynologues du nicotinamide et de l'isoniazide. J. Heterocycl. Chem. 1981, 18:519-523.
37. Babin P., Lapouyade P., Dunoguès J. Synthesis of chalcone ethynologues with a pharmacological objective. Canad. J. Chem. 1982, 60:379-382.
38. Hoffmeister F. Zur Frage pharmakologisch-klinischer Wirkungsbeziehungen bei Antidepressiva, dargestellt am Beispiel von Noxiptilin. Arzneimitt.-Forsch. 1969, 19:458-467.
39. Leclerc G., Mann A., Wermuth C.G., Bieth N., Schwartz J. Synthesis and β-adrenergic blocking activity of a novel class of aromatic oxime ethers. J. Med. Chem. 1977, 20:1657-1662.
40. 2-adrenoceptor blocking agent. Br. J. Pharmacol. 1977, 357-362.
41. Leclerc G., Bieth N., Schwartz J. Synthesis and β-adrenergic blocking activity of new aliphatic oxime ethers. J. Med. Chem. 1980, 23:620-624.
42. Macchia B., Balsamo A., Lapucci A., Martinelli A., Macchia F., Bresci M.C., Fantoni B., Martinotti E. An interdisciplinary approach to the design of new structures active at the β-adrenergic receptor. Aliphatic oxime ether derivatives. J. Med. Chem. 1985, 28:153-160.
43. Aichinger G., Behner O., Hoffmeister F., Schütz S. Basische tricyclische Oximinoäther und ihre pharmakologischen Eigenschaften. Arzneimitt.-Forsch. 1969, 19:838-845.
44. Bandoli G., Nicolini M. Crystal structure of the antidepressant noxiptyline hydrochloride (5-dimethylaminoethyloximino-5H-dibenzo[a,d]-cyclohepta-1,4-diene hydrochloride). J. Crystallogr. Spectrosc. Res. 1983, 13:191-199.
45. Valenti P., Mazzotti M., Rampa A., Magistretti M.J. Cyclovinylogues of procainamide. Arch. Pharm. 1982, 315:1003-1007.
46. Valenti P., Montanari P., Da Re P., Soldani G., Bertelli A. Synthesis and pharmacological properties of three lidocaine cyclovinylogues. Arch. Pharm. 1980, 313:280-284.
47. Valenti P., Montanari P., Fabbri G., Giovannini L., Giacomelli A. Cyclo-vinylogues of some antimuscarinic drugs. Arch. Pharm. 1985, 318:222-224.
48. Mooriya T., Seki M., Takabe S., Matsumoto K., Takashima K., Mori T. Compound TA-1801 [ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate]. J. Pharm. Sci. 1987, 76:S164.
49. Smith A.B., Keenan T.P., Holcomb R.C., Sprengeler P.A., Guzman M.C., Wood J.L., Caroll P.J., Hirschmann R. Design synthesis and crystal structure of a pyrrolinone-based peptidomimetic possessing the conformation of a β-strand: potential application to the design of novel inhibitors of proteolytic enzymes. J. Am. Chem. Soc. 1992, 114:10672-10674.
50. Cottis S.G., Clarke P.B., Tieckelmann H. Pyrazolo[3,4-b]pyridines and pyrazolo[3',4':6,5]pyrido[2,3-d]pyrimidines. J. Heterocycl. Chem. 1965, 2:192-201.
51. Leonard N.J., Morrice A.G., Sprecker M.A. Linear benzoadenine. A stretched-out analog of adenine. J. Org. Chem. 1975, 40:356-363.
52. Morrice A.G., Sprecker M.A., Leonard N.J. The angular benzoadenines. 9-Aminoimidazo [4,5-f] quinazoline and 6-aminoimidazo [4,5-h] quinazoline. J. Org. Chem. 1975, 40:363-366.
53. Leonard N.J., Sprecker M.A., Morrice A.G. Defined dimensional changes in enzyme substrates and cofactors. Synthesis of lin-benzoadenosine and enzymatic evaluation of derivatives of the benzopurines. J. Am. Chem. Soc. 1976, 98:3987-3994.
54. Leonard N.J., Hiremath S.P. Dimensional probes of binding and activity. Tetrahedron 1986, 42:1917-1961.
55. Schneller S.W., Ibay A.C., Christ W.J., Bruns R.F. Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists. J. Med. Chem. 1989, 32:2247-2254.
56. Jordis U., Sauter F., Rudolf M., Cai G. Synthesen neuer Chinolon-Chemotherapeutika 1: Pyridochinoline und Pyridophenanthroline als "lin-benzo-Nalidixinsäure"-Derivate. Monatsh. Chem. 1988, 119:761-780.
57. Rotella D.P., Sun Z., Zhu Y., Krupinski J., Pongrac R., Seliger L., Normandin D., Macor J.E. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. J. Med. Chem. 2000, 43:1257-1263.
58. Averkin E.A., Beard C.C., Dvorak C.A., Edwards J.A., Fried J.H., Kilian J.G., Schiltz R.A., Kistner T.P., Drudge J.H., Lyons E.T., Sharp M.L., Corwin R.M. Methyl 5(6)-phenylsulfinyl-2-benzimidazolecarbamate, a new, potent anthelmintic. J. Med. Chem. 1972, 15:1164-1166.
59. Bochis R.J., Dybas R.A., Eskola P., Kulsa P., Linn B.O., Lusi A., Meitzner E.P., Milkowski J., Mrozik H., Olen L.E., Peterson L.H., Tolman R.L., Wagner A.F., Waksmunski F.S. Methyl 6-(phenylsulfinyl) imidazo [1,2-a] pyridine-2-carbamate, a potent, new anthelmintic. J. Med. Chem. 1978, 21:235-237.